“Selling unapproved products with unsubstantiated therapeutic claims … can put patients and consumers at risk by leading them to put off important medical care,” said acting FDA Commissioner Ned Sharpless. “Additionally, there are many unanswered questions about the science, safety, effectiveness, and quality of unapproved products containing CBD.”